

# National Infrastructure for Chemical Biology



## Mission:

Identification and development of new molecular probes/tools for research and new potential therapeutics

## Key components of the infrastructure:

Units for high-throughput screening - HTS - **Open Access**

National compound collection + mirror site of Screening library of EU-OPENSOURCE

National database – link to ECBD

Support:     Assay development & High-throughput screening  
                 Medicinal chemistry  
                 Compound profiling & ADME/TOX  
                 Cheminformatics

CZ-OPENSOURCE is on the

Roadmap for Large Research,  
Development and Innovation  
Infrastructures in the Czech Republic

Ministry of Education, Youth and Sports



# National Infrastructure for Chemical Biology



# National Infrastructure for Chemical Biology



Institute of Molecular Genetics of the ASCR, v.v.i.

[Core Facilities](#) [Other Facilities](#) [Jobs](#) [Links](#) [Public Tenders](#)

[Home](#) [About](#) [Research](#) [Achievements](#) [Education](#) [Events](#) [News](#) [Contact](#)



RESEARCH

You are here: [Home](#) > Research

Research Groups

Research-Service Groups

Research Infrastructures



National Infrastructure for  
Chemical Biology



Czech Centre for  
Phenogenomics




Czech - Bioimaging

Institute of Molecular Genetics is a member of:

[BIOCEV z. s. p. o.](#) [CzechBIO](#) [Technology Centre of the ASCR](#) [Infrafrontier GmbH](#)

# National Infrastructure for Chemical Biology

How we are connected with other BMS infrastructures?



# National Infrastructure for Chemical Biology

Where we get an advice from?

## International Scientific Advisory Board



Kjetil Tasken  
BiO, Oslo  
Norway



Phil Gribbon  
FMP, Berlin  
Germany



Mikael Elofsson  
Umeå University  
Sweden



John Overington  
Medicines Discovery  
Catapult, London, UK



Jordi Quintana  
PCB, Barcelona  
Spain

## Open Access Committee



Cyril Bařinka  
IBT AS CR  
Prague



Marek Jindra  
Biology Center AS CR  
České Budějovice



Jiří Jiráček  
IOCB AS CR  
Prague



Martin Pospíšek  
Charles University  
Prague



# National Infrastructure for Chemical Biology

What is the long-term development strategy and ambitions (10 years+)?

ERIC, trans-national open access, excellent science...

go more translational

Upgrade of technology (new trends, state-of-the-art)

How does your large research infrastructure fit the progressive trends and of the community?

Selection of the best projects via Open Access procedure

stay cutting-edge..., trying to serve the users

What makes your large research infrastructure attractive for the industry?

Technology access for SMEs

“Risky” or “complicated/sophisticated” science for large Pharma

What is the most valuable feedback from evaluation committee

PR and presentation to public, visibility to industry, private foundations and patient advocacy groups

Missing SWOT for changing scientific and industry landscape  
technology upgrade to enable prioritization...

Standardization (SOP, ISO, GLP...)